Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 months ago

Possible Interaction: Inosine and Mycophenolate Mofetil

Research Papers that Mention the Interaction

MMF inhibits the inosine monophosphate dehydrogenase that has been shown to have in vitro antiviral properties against flaviviruses, suggesting the possibility that it might also inhibit the hepatitis C virus (HCV).
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society  •  2003  |  View Paper
Mycophenolate-mofetil (MMF) is an inhibitor of inosine monophosphate dehydrogenase, which is necessary for de novo purine biosynthesis in lymphocytes.
Journal of Neurology  •  2001  |  View Paper
MMF , a non-competitive inhibitor of inosine monophosphate dehydrogenase, blocks de novo purine synthesis in T and B lymphocytes, resulting in the selective inhibition of proliferation of these cells in response to antigenic stimuli.
Expert opinion on pharmacotherapy  •  2003  |  View Paper
Mycophenolate mofetil (MMF) is an inhibitor of inosine monophosphate dehydrogenase, which affects de novo purine synthesis and T- and B-cell proliferation.
Przeglad lekarski  •  2013  |  View Paper
MMF selectively inhibits inosine 5′-monophosphate dehydrogenase type II, responsible for de novo synthesis of the purine nucleotide guanine.
Journal of Neurology, Neurosurgery & Psychiatry  •  2013  |  View Paper
MMF is an irreversible inhibitor of inosine monophosphate dehydrogenase in lymphocytes and affects lymphocytic proliferation and activation.
Pediatric transplantation  •  2011  |  View Paper
Mycophenolate mofetil (MMF) is an inhibitor of inosine monophosphate dehydrogenase and thus de novo purine synthesis.
Current medicinal chemistry  •  2010  |  View Paper
Via its metabolite mycophenolic acid (MPA), MMF interferes with the metabolic pathway of de novo purine synthesis through inhibition of inosine monophosphate dehydrogenase, suppressing both B and T lymphocyte proliferation3.
The Journal of Rheumatology  •  2009  |  View Paper
MMF is a selective inhibitor of inosine monophosphate dehydrogenase, thus blocking purine synthesis via the de novo pathway preferentially used by T and B lymphocytes.
Graefe's Archive for Clinical and Experimental Ophthalmology  •  2005  |  View Paper
Background MMF is a potent immunosuppressant that is a selective inhibitor of inosine 5′-monophosphate dehydrogenase type II, the enzyme responsible for the de novo synthesis of the purine nucleotide guanine within activated T and B lymphocytes and macrophages.
Clinical neuropharmacology  •  2004  |  View Paper
Show More